Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. - Wikidata - wikimedia - TriplyDB

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

http://www.wikidata.org/entity/Q35764302

about

A highlight from the LUPUS 2014 meeting: eight great ideas Update on pathogenesis and treatment of CLE Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus.Review of treatment for discoid lupus erythematosus.Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.Chloroquine improves the response to ischemic muscle injury and increases HMGB1 after arterial ligation.Cutaneous lupus erythematosus: diagnosis and treatment.Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review.Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.Mepacrine as successful monotherapy for refractory Jessner-Kanof disease: still an important drug in the dermatologic armamentarium.Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.Measurement of disease severity in cutaneous autoimmune diseases.Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study.Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy.Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.Lupus community panel proposals for optimising clinical trials: 2018.S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review

P2860

Q26823803-6926F880-5BBA-466E-8221-8E36F71BD0A3 Q26827054-368E1694-18FE-4670-96E1-AA102B3E7D9A Q33913777-41B47C75-3056-48F4-9BCE-1EA956633189 Q34650392-197A202A-7C3D-4BE4-86FC-647932778598 Q35987968-4D12C019-A6AF-42C0-BFCA-5EAF884C26EF Q36257051-1F897B08-5B59-4359-9623-FE34CCA7267E Q36297374-84FDF581-4FD1-40B9-9B52-B80A4D61F371 Q37590352-7F40330F-0E06-4246-96AF-9E186623E2B4 Q37591236-1E90B76E-E009-4D39-A892-E181E68B334D Q38026787-F6FF6337-0C91-4839-9C99-65EAF49530A3 Q38178160-7C435B6B-8BF9-4993-8A58-EBE8590A3D67 Q38360827-5DF6756C-4C0F-487C-AFE8-B8F7B23361D2 Q38731631-EBA60ECE-D1EA-4C5A-94A7-561F2CE014FD Q38816297-0A2E8A59-4DD8-4B4E-8B08-9EFAA77B9E02 Q38850089-2642A3CF-3D4E-40E1-B398-D428150A4974 Q38857518-2ABC7891-5998-49EB-8A48-93B2E7F8A689 Q41558860-9F92034D-9C90-4995-B1AB-AD3513C490DF Q41911782-8998C70E-16BC-4AF8-89FB-8C37ADF7BA6F Q41913718-032CAC6D-2958-4ACE-BE73-CC7653A6A4D8 Q47103957-DA57907D-9DA2-4DCF-A11E-24D783925048 Q47760514-562B5E2E-A1C8-4991-87D0-EF60F351A6C7 Q47826297-73952718-17EF-4790-A04A-9083CEF9F761 Q51150943-425B4A92-1C37-40C1-BE20-6AE9CBB54943 Q52320880-3D989EDF-9F2C-45BB-9841-E67152DEFA27 Q52836583-9D3976A3-9334-41A9-98D2-B9D74D8B8B70 Q58740305-AC95C244-2DA6-41D8-A2EB-E45DEF2C7919

P2860

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

http://www.wikidata.org/entity/Q35764302

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@ast

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@en

type

label

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@ast

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@en

prefLabel

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@ast

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@en

P1433

Q35764302-A7887130-9BAC-4AB0-A52E-9BA47FD152F6

P1476

Q35764302-19193999-65A6-4A39-A407-72369EA84740

P2093

Q35764302-07051D90-1B93-4166-B69E-BE7B1680E36C

Q35764302-3C20D675-F9F2-4D71-AD7D-59261132BF19

Q35764302-54E1F0A6-188C-427C-A095-C8AC86487B9E

Q35764302-71C8DFCD-5084-4C96-BF1F-2A87C1903CB7

Q35764302-96BF44BB-F553-4923-BC74-5249D5EA0B5E

Q35764302-A8F1A3E4-1C81-4221-80D4-1653D0A1F5CE

P2860

Q35764302-02EBCC50-D11F-43DF-B8B3-5301157134BE

Q35764302-031EE9F9-6442-45B1-AE51-27B27B3E3381

Q35764302-0EA86679-2F22-47AD-ACC9-065F477A4BEA

Q35764302-21276D00-9476-4DE6-AEB0-EF34CAF957DF

Q35764302-29C0C7C5-10B5-4FD3-9F00-5CF754875E9F

Q35764302-29C7194E-132A-46F1-BF93-E59C9F8CEE0A

Q35764302-3116FE0E-B1DD-4D2F-8E09-C61B998AF60B

Q35764302-3E953ABB-251A-4DF4-996D-2665907EE6BB

Q35764302-3EB92377-7BD1-427D-8CC9-F111CE2EFDD3

Q35764302-52CA9E73-2AC3-4C7C-97EC-9D0CC24AA323

P304

Q35764302-9C66B282-595F-42F3-9C47-804965E4B17B

P31

Q35764302-584230F1-E030-4B04-AB33-66D86835F25D

P356

Q35764302-B92ACC31-FB08-44E7-B13B-05391CC1B3B6

P433

Q35764302-EA53580C-9C8C-4921-BC4E-F968666C2814

P478

Q35764302-5F1393DF-80E7-4FE2-8A84-0D003281DE4E

P577

Q35764302-A7BA88D3-F4A8-46E8-BB09-ABB2FCBCE070

P5875

Q35764302-6AD7ADB5-5D20-4778-AB3C-9D71DBCABF7C

P698

Q35764302-72EA3570-4BE0-406F-B756-963490CE3BDC

P921

Q35764302-FBA07B8F-AB59-4F47-93CD-070731F54120

P932

Q35764302-5FC197A4-3CE8-43A5-B6D4-EF32110CEEE0

P356

ARCHDERMATOL.2011.191

P1433

JAMA Dermatology

P1476

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

@en

P2093

Aileen Y Chang

http://www.w3.org/2001/XMLSchema#string

Evan W Piette

http://www.w3.org/2001/XMLSchema#string

Joyce Okawa

http://www.w3.org/2001/XMLSchema#string

Kristen P Foering

http://www.w3.org/2001/XMLSchema#string

Thomas R Tenhave

http://www.w3.org/2001/XMLSchema#string

Victoria P Werth

http://www.w3.org/2001/XMLSchema#string

P2860

Drugs for discoid lupus erythematosus

Wilcoxon-Mann-Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules

Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus

The 1982 revised criteria for the classification of systemic lupus erythematosus

Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus.

The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.

Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.

New concepts in antimalarial use and mode of action in dermatology.

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.

Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.

P304

1261-1267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHDERMATOL.2011.191

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51501548

http://www.w3.org/2001/XMLSchema#string

P698

21768444

http://www.w3.org/2001/XMLSchema#string

P921

P932

3282057

http://www.w3.org/2001/XMLSchema#string